M G Sanal

Summary

Affiliation: University of Copenhagen
Country: Denmark

Publications

  1. ncbi Essential fatty acid deficiency in patients receiving home parenteral nutrition
    P B Jeppesen
    Department of Medicine, Rigshospitalet, University of Copenhagen, Denmark
    Am J Clin Nutr 68:126-33. 1998
  2. ncbi Nonalcoholic fatty liver disease: the concept and confusion
    M G Sanal
    Institute of Liver and Biliary Sciences, New Delhi, India
    Minerva Gastroenterol Dietol 57:419-26. 2011
  3. ncbi Modern treatment of adult short bowel syndrome patients
    E Efsen
    Department of Gastroenterology CA 2121 Rigshospitalet, Copenhagen, Denmark
    Minerva Gastroenterol Dietol 57:405-17. 2011
  4. ncbi Randomised placebo-controlled trial of teduglutide in reducing parenteral nutrition and/or intravenous fluid requirements in patients with short bowel syndrome
    P B Jeppesen
    Department of Gastroenterology CA 2121, Rigshospitalet, Copenhagen, Denmark
    Gut 60:902-14. 2011
  5. ncbi [Short-bowel syndrome treated with glucagon-like peptide. 2. The Danish Society for Gastroenterology]
    Palle Bekker Jeppesen
    Medicinsk gastroenterologisk afdeling, Abdominalcentret, Rigshospitalet,
    Ugeskr Laeger 170:1024. 2008
  6. ncbi Growth factors in short-bowel syndrome patients
    Palle Bekker Jeppesen
    Department of Medical Gastroenterology, CA 2121, Rigshospitalet, Blegdamsvej 9, DK 2100 Copenhagen, Denmark
    Gastroenterol Clin North Am 36:109-21, vii. 2007
  7. ncbi Glucagon-like peptide-2: update of the recent clinical trials
    Palle Bekker Jeppesen
    Department of Medicine, Section of Gastroenterology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
    Gastroenterology 130:S127-31. 2006
  8. ncbi Teduglutide (ALX-0600), a dipeptidyl peptidase IV resistant glucagon-like peptide 2 analogue, improves intestinal function in short bowel syndrome patients
    P B Jeppesen
    Department of Medicine CA 2121, Section of Gastroenterology, Rigshospitalet, University Hospital of Copenhagen, Blegdamsvej 9, DK 2100 Copenhagen, Denmark
    Gut 54:1224-31. 2005
  9. ncbi Experimental approaches: dietary and hormone therapy
    P B Jeppesen
    Department of Medicine CA 2121, Section of Gastroenterology, Rigshospitalet, University of Copenhagen, Blegdamsvej 9, DK 2100, Copenhagen, Denmark
    Best Pract Res Clin Gastroenterol 17:1041-54. 2003
  10. ncbi Clinical significance of GLP-2 in short-bowel syndrome
    P B Jeppesen
    Department of Medicine CA 2121, Section of Gastroenterology, Rigshospitalet, University of Copenhagen, DK 2100 Copenhagen, Denmark
    J Nutr 133:3721-4. 2003

Detail Information

Publications21

  1. ncbi Essential fatty acid deficiency in patients receiving home parenteral nutrition
    P B Jeppesen
    Department of Medicine, Rigshospitalet, University of Copenhagen, Denmark
    Am J Clin Nutr 68:126-33. 1998
    ..Parenteral lipids did not increase the concentration of essential fatty acids to values comparable with those of control subjects, but 500 mL 20% Intralipid once a week was sufficient to prevent an increase in the Holman index above 0.2...
  2. ncbi Nonalcoholic fatty liver disease: the concept and confusion
    M G Sanal
    Institute of Liver and Biliary Sciences, New Delhi, India
    Minerva Gastroenterol Dietol 57:419-26. 2011
    ..Currently fatty liver disease could be considered as an added Hepato-cardiovascular-renal and cancer risk factor rather than a specific diagnosis...
  3. ncbi Modern treatment of adult short bowel syndrome patients
    E Efsen
    Department of Gastroenterology CA 2121 Rigshospitalet, Copenhagen, Denmark
    Minerva Gastroenterol Dietol 57:405-17. 2011
    ....
  4. ncbi Randomised placebo-controlled trial of teduglutide in reducing parenteral nutrition and/or intravenous fluid requirements in patients with short bowel syndrome
    P B Jeppesen
    Department of Gastroenterology CA 2121, Rigshospitalet, Copenhagen, Denmark
    Gut 60:902-14. 2011
    ..This 24-week placebo-controlled study evaluated the ability of teduglutide to reduce parenteral support in patients with SBS with intestinal failure...
  5. ncbi [Short-bowel syndrome treated with glucagon-like peptide. 2. The Danish Society for Gastroenterology]
    Palle Bekker Jeppesen
    Medicinsk gastroenterologisk afdeling, Abdominalcentret, Rigshospitalet,
    Ugeskr Laeger 170:1024. 2008
  6. ncbi Growth factors in short-bowel syndrome patients
    Palle Bekker Jeppesen
    Department of Medical Gastroenterology, CA 2121, Rigshospitalet, Blegdamsvej 9, DK 2100 Copenhagen, Denmark
    Gastroenterol Clin North Am 36:109-21, vii. 2007
    ....
  7. ncbi Glucagon-like peptide-2: update of the recent clinical trials
    Palle Bekker Jeppesen
    Department of Medicine, Section of Gastroenterology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
    Gastroenterology 130:S127-31. 2006
    ....
  8. ncbi Teduglutide (ALX-0600), a dipeptidyl peptidase IV resistant glucagon-like peptide 2 analogue, improves intestinal function in short bowel syndrome patients
    P B Jeppesen
    Department of Medicine CA 2121, Section of Gastroenterology, Rigshospitalet, University Hospital of Copenhagen, Blegdamsvej 9, DK 2100 Copenhagen, Denmark
    Gut 54:1224-31. 2005
    ..The safety and effect of teduglutide were investigated in SBS patients with and without a colon in continuity...
  9. ncbi Experimental approaches: dietary and hormone therapy
    P B Jeppesen
    Department of Medicine CA 2121, Section of Gastroenterology, Rigshospitalet, University of Copenhagen, Blegdamsvej 9, DK 2100, Copenhagen, Denmark
    Best Pract Res Clin Gastroenterol 17:1041-54. 2003
    ..Overall, the ultimate aim in the treatment of SBS patients is to optimize remnant intestinal function, thereby eliminating the need for parenteral support and improving quality of life in these patients...
  10. ncbi Clinical significance of GLP-2 in short-bowel syndrome
    P B Jeppesen
    Department of Medicine CA 2121, Section of Gastroenterology, Rigshospitalet, University of Copenhagen, DK 2100 Copenhagen, Denmark
    J Nutr 133:3721-4. 2003
    ....
  11. ncbi Treatment of adult short bowel syndrome patients with teduglutide
    Lærke Marijke Nørholk
    Department of Medicine CA 2121, Rigshospitalet, Blegdamsvej 9, DK 2100 Copenhagen, Denmark
    Expert Opin Pharmacother 13:235-43. 2012
    ....
  12. ncbi Differences in essential fatty acid requirements by enteral and parenteral routes of administration in patients with fat malabsorption
    P B Jeppesen
    Department of Medicine, Section of Gastroenterology CA, Rigshospitalet, University of Copenhagen, Denmark
    Am J Clin Nutr 70:78-84. 1999
    ..Essential fatty acid (EFA) requirements of patients receiving home parenteral nutrition (HPN) are uncertain...
  13. ncbi Elevated plasma glucagon-like peptide 1 and 2 concentrations in ileum resected short bowel patients with a preserved colon
    P B Jeppesen
    Department of Medicine CA 2121, Section of Gastroenterology, Rigshospitalet, University of Copenhagen, Denmark
    Gut 47:370-6. 2000
    ..Ileum resected short bowel patients with a preserved colon show evidence of functional adaptation and have normal gastric emptying...
  14. ncbi Deficiencies of essential fatty acids, vitamin A and E and changes in plasma lipoproteins in patients with reduced fat absorption or intestinal failure
    P B Jeppesen
    Department of Medicine CA, Section of Gastroenterology, Rigshospitalet, Copenhagen, Denmark
    Eur J Clin Nutr 54:632-42. 2000
    ....
  15. ncbi Effect of high-dose growth hormone and glutamine on body composition, urine creatinine excretion, fatty acid absorption, and essential fatty acids status in short bowel patients: a randomized, double-blind, crossover, placebo-controlled study
    P B Jeppesen
    Dept of Medicine CA, Rigshospitalet, University of Copenhagen, Denmark
    Scand J Gastroenterol 36:48-54. 2001
    ....
  16. ncbi Glucagon-like peptide 2 improves nutrient absorption and nutritional status in short-bowel patients with no colon
    P B Jeppesen
    Department of Medicine, Section of Gastroenterology, Rigshospitalet, University Hospital of Copenhagen, Denmark
    Gastroenterology 120:806-15. 2001
    ..5 kg/day) and energy (>2.3 MJ/day) and no postprandial secretion of GLP-2...
  17. ncbi Enhancing bowel adaptation in short bowel syndrome
    Palle Bekker Jeppesen
    Department of Medicine CA 2121, Section of Gastroenterology, Rigshospitalet, University of Copenhagen, Blegdamsvej 9, DK 2100 Copenhagen, Denmark
    Curr Gastroenterol Rep 4:338-47. 2002
    ..Results of clinical trials employing either growth hormone and glutamine or glucagon-like peptide-2 in short bowel patients are presented...
  18. ncbi The effect of Glucagon-Like Peptide-2 on mesenteric blood flow and cardiac parameters in end-jejunostomy short bowel patients
    Lasse Bremholm
    Department of Gastroenterology, Køge Hospital, University of Copenhagen, Denmark
    Regul Pept 168:32-8. 2011
    ..The aim of the study was to evaluate the effect of GLP-2 on mesenteric blood flow and dynamic changes in cardiac parameters in SBS patients with jejunostomy and varying length of remnant small intestine...
  19. ncbi Intestinal insufficiency and failure
    Palle Bekker Jeppesen
    Department of Medical Gastroenterology, H:S Rigshospitalet, Copenhagen
    Dan Med Bull 50:238-61. 2003
  20. ncbi The truncated metabolite GLP-2 (3-33) interacts with the GLP-2 receptor as a partial agonist
    Jesper Thulesen
    Department of Medical Anatomy, Section B, The Panum Institute, University of Copenhagen, Blegdamsvej 3, 2200 N, Copenhagen, Denmark
    Regul Pept 103:9-15. 2002
    ..Consistent with the observed in vivo activities, our functional studies and binding data indicate that GLP-2 (3-33) acts as a partial agonist with potential competitive antagonistic properties on the GLP-2 receptor...
  21. ncbi Short bowel syndrome and intestinal failure: consensus definitions and overview
    Stephen J D O'Keefe
    Division of Gastroenterology, Hepatology, and Nutrition, University of Pittsburgh, Pittsburgh, Pennsylvania 15213, USA
    Clin Gastroenterol Hepatol 4:6-10. 2006
    ..quot;..